Propafenone during acute myocardial ischemia in patients: A double-blind, randomized, placebo-controlled study

Journal of the American College of Cardiology

Volumn 29, Issue 3, 1997, Pages 561-567

  Faber, Thomas S ^a   Zehender, Manfred ^a   Krahnefeld, Olaf ^b   Daisenberger, Karin ^a   Meinertz, Thomas ^b   Just, Hanjörg ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROPAFENONE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REPOLARIZATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROPAFENONE; PROSPECTIVE STUDIES;

EID: 0031043409     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00555-4     Document Type: Article

References (48)

1. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
2. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium - phase 2 reentry? Circulation 1993;87:562-72.
3. Podrid PJ, Morgenroth J. Aggravation of arrhythmia during drug therapy [abstract]. Prac Cardiol 1985;11:55.
4. Velbit V, Podrid P, Lown P, Cohnen BH, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982;65:886-94.
5. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 1991;5:515-30.
6. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcomes. N Engl J Med 1988;318:19-24.
7. Nattel S, Pedersen DH, Zipes DP. Alterations in regional myocardial distribution and arrhythmogenic effects of aprinidine produced by coronary artery occlusion in the dog. Cardiovasc Res 1989;15:80-5.
8. Morady F, Di Carlo L, Grol R, et al. Role of myocardial ischemia during programmed stimulation in survivors of cardiac arrest with coronary artery disease. J Am Coll Cardiol 1987;9:1004-12.
9. Gomes AJ, Elexopoulos D, Winters SL, Desmukh P, Fuster V, Suh KRN. The role of silent ischemia, the arrhythmic substrate and the short-long sequence in the genesis of sudden cardiac death. J Am Coll Cardiol 1989;14:1618-25.
10. Whitaker MP, Sheps DS. Prevalence of silent myocardial ischemia in survivors of cardiac arrest. Am J Cardiol 1989;64:591-3.
11. Morgenroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987;59:32E-7E.
12. Rosenfeld J, Rosen MR, Hoffman BF. Pharmacologic and behavioral effects on arrhythmias that immediately follow abrupt coronary occlusion: a canine model of sudden coronary death. Am J Cardiol 1978;41:1075-82.
13. Koyanagi S, Eastham C, Marcus ML. Effects of chronic hypertension and left ventricular hypertrophy on the incidence of sudden cardiac death after coronary artery occlusion in conscious dogs. Circulation 1982;65:1192-7.
14. Levites R, Banka VS, Helfant RH. Electrophysiologic effects of coronary occlusion and reperfusion - observations of dispersion of refractoriness and ventricular automaticity. Circulation 1975;52:760-5.
15. Hondeghem LM. Effects of lidocaine, phenytoin and quinidine on the ischemic canine myocardium. J Electrocardiol 1986;9:203-10.
16. Schwartz P, Wolf S. QT-interval prolongation as a predictor of sudden death in patients with myocardial infarction. Circulation 1978;57:1074-7.
17. Toshio A, Greenberg H, Chien K, Fowles R, Reynolds R. CAST Investigators: increased risk of death from encainide/flecainide in non-Q wave myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Circulation 1990;82 Suppl II:II-138.
18. Anderson JL, Platia EV, Hallstrom A, et al, for the Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction: a possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation 1994;90:2843-52.
19. Higham PD, Furniss SS, Campbell RWF. QT dispersion and components of the QT interval in ischemia and infarction. Br Heart J 1995;73:32-6.
20. Hii JTY, Wyse G, Gillis AM, Duff HJ, Solylo MA, Mitchell B. Precordial QT dispersion as a marker of torsade de pointes - disparate effects of class Ia antiarrhythmic drugs and amiodaron. Circulation 1992;86:1376-82.
21. Schechter JA, Caine R, Friehling T, Kowey PR, Engel TR. Effect of procainamide on dispersion of ventricular refractoriness. Am J Cardiol 1983;52:279-82.
22. Buja G, Miorelli M, Turrini P, Melacini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993;72:973-6.
23. Mirvis DM. Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction. J Am Coll Cardiol 1985;5:625-31.
24. Surawicz B. Dispersion of refractoriness in ventricular arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology. Philadelphia: WB Saunders, 1990:377-86.
25. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-4.
26. Day CP, McComb JM, Matthews J, Campbell RWF. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991;12: 423-7.
27. Day CP, McComb JM, Campbell RWF. QT dispersion in sinus beats and ventricular extrasystoles in normal heart. Br Heart J 1992;67:39-41.
28. Pye M, Quinn AC, Cobbe SM. QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? Br Heart J 1994;71:511-4.
29. Barr CS, Naas A, Freeman M, Lang CC, Dtruthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-9.
30. Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Br Heart J 1994;71:268-73.
31. Hohnloser SH, van de Loo A, Arendts W, Zabel M, Just H. QT dispersion in the surface ECG as a parameter of increased electrical vulnerability in acute myocardial ischemia. Z Kardiol 1993;82:678-82.
32. Cowan CJ, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1986;61:83-7.
33. Zehender M, Hohnloser S, Just H. Silent myocardial ischemia and malignant ventricular arrhythmias in patients undergoing percutaneous transluminal angioplasty. Circulation 1988;78 Suppl II:II-8.
34. Hope RR, Williams DO, El-Sherif N, Lazzara R, Scherlag BJ. The efficacy of antiarrhythmic agents during acute myocardial ischemia and the role of heart rate. Circulation 1974;50:507-14.
35. Euler DE, Spear JF, Moore EN. Effect of coronary occlusion on arrhythmias and conduction in the ovine heart. Am J Physiol 1983;245:H82-9.
36. Kaplinsky E, Ogawa S, Balke W, Dreifus LS. Role of endocardial activation in malignant ventricular arrhythmias associated with acute ischemia. J Electrocardiol 1979;12:299-306.
37. Thomas A, Knapman P, Krikler D, Davis MJ. Community study of the cause of "natural" sudden death. Br Med J 1988;85 Suppl I:I-118-24.
38. Stevenson WG, Linssen GC, Havenith MG, Brugada P, Wellens HJ. The spectrum of death after myocardial infarction: a necropsy study. Am Heart J 1989;118:1182-8.
39. Bayes de Luna A, Coumel P, Leclerq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmias on the basis of data from 157 cases. Am Heart J 117,1:151-9.
40. Holmes DR, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation 1986;73:1254-63.
41. Levine JH, Mellitis DE, Baumgartner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverterdefibrillator. Circulation 1991;84:558-66.
42. Wang FS, Lien WP, Fong TE, et al. Terminal cardiac electrical activity in adults who die without apparent cardiac disease. Am J Cardiol 1986;58: 491-5.
43. Shimizu H, Inoueb T, Itagaki T, Sekiya J. QT dispersion in patients with polymorphic ventricular tachycardia [abstract]. Circulation 1994;90 Suppl I:I-662.
44. Cui G, Sager P, Uppal P, Sing BN. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994;74:896-900.
45. Moreno FL, Villanueva T, Karagounis LA, Anderson JL. Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. Circulation 1994;90:94-100.
46. Dritsas A, Gilligan D, Nihoyannopoulos P, Oakley CM. Amiodaron reduces QT dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol 1992;36:345-9.
47. Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA. Clinical pharmacology of propafenone. Circulation 1983;68:589-96.
48. Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.